Levodopa‐Carbidopa Intestinal Gel Improves Dyskinesia in Parkinson's Disease: Post Hoc Analysis from the COSMOS Study
Movement Disorders Clinical Practice · 2026
DOI: 10.1002/mdc3.70222 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Movement Disorders Clinical Practice, 2026. Verfasst von Alfonso Fasano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Edmond J Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Division of Neuro…. Hauptthemen laut MEDLINE: Carbidopa, Levodopa, Parkinson Disease, Antiparkinson Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Background
Dyskinesia is a debilitating complication of dopaminergic therapy in advanced Parkinson's disease.
Objectives
To evaluate the effect of levodopa‐carbidopa intestinal gel ( LCIG ) on dyskinesia burden.
Methods
This is a post hoc analysis of the retrospective, observational CO medication S tudy assessing M ono‐ and c O mbination therapy with levodopa‐carbidopa inte S tinal gel ( COSMOS ; NCT03362879 ). Change in dyskinesia was assessed by LCIG treatment group (monotherapy, daytime monotherapy, polytherapy), baseline dyskinesia duration (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Edmond J Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Division of Neurology, UHN, Division of Neurology, University of Toronto, Toronto, ON,…
- Krembil Research Institute, Toronto, ON, Canada.
- Neurology Department, University General Hospital of Heraklion PA.G.N.I, Heraklion, Greece.
- Movement Disorders Unit, Neurological Institute, Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel.
- Department of Neurology and Center of Clinical Neurosciences, First Faculty of Medicine, Charles University in Prague, and General University Hospital in Prague, Prague, Czech Republic.
- Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Alfonso Fasano, Cleanthe Spanaki, Tanya Gurevich, Robert Jech, Per Svenningsson, József Szász, Lydia Vela-Desojo, Mihaela Simu, Abdallah Saad, Juan Carlos Parra, Norbert Kovács
Förderung
- AbbVie
Zitieren
APA
Fasano, A., Spanaki, C., Gurevich, T., Jech, R., Svenningsson, P., Szász, J., Vela-Desojo, L., Simu, M., Bergmann, L., Saad, A., Parra, J. C., & Kovács, N. (2026). Levodopa‐Carbidopa Intestinal Gel Improves Dyskinesia in Parkinson's Disease: Post Hoc Analysis from the COSMOS Study. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70222
Vancouver
Fasano A, Spanaki C, Gurevich T, Jech R, Svenningsson P, Szász J, et al. Levodopa‐Carbidopa Intestinal Gel Improves Dyskinesia in Parkinson's Disease: Post Hoc Analysis from the COSMOS Study. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70222
BibTeX
@article{Fasano2026,
author = {Fasano, Alfonso and Spanaki, Cleanthe and Gurevich, Tanya and Jech, Robert and Svenningsson, Per and Szász, József and Vela-Desojo, Lydia and Simu, Mihaela and Bergmann, Lars and Saad, Abdallah and Parra, Juan Carlos and Kovács, Norbert},
title = {Levodopa‐Carbidopa Intestinal Gel Improves Dyskinesia in Parkinson's Disease: Post Hoc Analysis from the COSMOS Study},
journal = {Movement Disorders Clinical Practice},
year = {2026},
doi = {10.1002/mdc3.70222}
}
EUVIMED